172 related articles for article (PubMed ID: 36460981)
1. Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy.
Jiang C; Xiu Y; Yu X; Qiao K; Zhang S; Huang Y
BMC Cancer; 2022 Dec; 22(1):1249. PubMed ID: 36460981
[TBL] [Abstract][Full Text] [Related]
2. Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy.
Xiu Y; Jiang C; Huang Q; Yu X; Qiao K; Wu D; Yang X; Zhang S; Lu X; Huang Y
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16097-16110. PubMed ID: 37698677
[TBL] [Abstract][Full Text] [Related]
3. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():831848. PubMed ID: 35320931
[TBL] [Abstract][Full Text] [Related]
4. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Jiang C; Zhang S; Qiao K; Xiu Y; Yu X; Huang Y
Clin Breast Cancer; 2022 Jul; 22(5):424-438. PubMed ID: 35428593
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of the Modified Systemic Inflammation Score in Patients With Extranodal Natural Killer/T-Cell Lymphoma.
Huang H; Chen LM; Fang XJ; Guo CC; Lin XP; Hong HM; Li X; Wang Z; Tian Y; Chen MT; Yao YY; Chen Z; Li XQ; Pan F
Front Pharmacol; 2020; 11():593392. PubMed ID: 33101044
[TBL] [Abstract][Full Text] [Related]
6. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
8. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
10. Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: A prognostic nomogram study.
Zheng Y; Wu C; Yan H; Chen S
Clin Chim Acta; 2020 Jul; 506():110-121. PubMed ID: 32156604
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
12. Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
Cancer Manag Res; 2020; 12():1543-1567. PubMed ID: 32184659
[TBL] [Abstract][Full Text] [Related]
13. A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study.
Wang MD; Duan FF; Hua X; Cao L; Xia W; Chen JY
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836576
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():849468. PubMed ID: 35669769
[TBL] [Abstract][Full Text] [Related]
15. A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
Jiang C; Xiu Y; Zhang S; Yu X; Qiao K; Huang Y
Dis Markers; 2022; 2022():8044550. PubMed ID: 36569222
[TBL] [Abstract][Full Text] [Related]
16. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
[No Abstract] [Full Text] [Related]
17. The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.
Gao S; Tang W; Zuo B; Mulvihill L; Yu J; Yu Y
Front Oncol; 2022; 12():1065606. PubMed ID: 36727046
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
